Genmab upgrades financial guidance again
Darzalex sales are going so well that Genmab has increased its top and bottom line expectations. It also now expects lower costs than previously estimated.
by viktor emil kristensen, translated by catherine brett
Sales of Darzalex, which is a bone marrow cancer drug, are significantly exceeding expectations, Genmab reports in a stock exchange notification.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Horizon's Genmab drug gets blockbuster status
For subscribers
Analysts say Darzalex sales prognosis could be too cautious
For subscribers
